Author
Year
Design
Rate
Comments
Prissel and Roukis [1]
2013
STAR
10.7%
No comments
Labek et al. [4]
2013
Multiple designs
10% (40% for aseptic loosening)
Registry data from Sweden, Finland, Norway, New Zealand, and Australia were included in this analysis
Noelle et al. [5]
2013
STAR
14.9%
No comments
Roukis and Elliott [3]
2015
Salto mobile and Salto-Talaris
From 2.6% to 5.2% (Salto mobile); from 2% to 2.8% (Salto-Talaris)
Restricting the data to the inventor, design team, or disclosed consultants, the incidence of revision was 5.2% for the Salto mobile version and 2.6% for the Salto-Talaris TAAs. In contrast, data that excluded these individuals had an incidence of revision of 2.8% for the Salto mobile version and 2% for the Salto-Talaris TAAs. The incidences of revision for the Salto mobile version and Salto-Talaris TAAs were lower than those reported through systematic review for the Agility and STAR systems without obvious selection (inventor) or publication (conflict of interest) bias
Lai et al. [6]
2015
NA
9.6%
No comments
Law et al. [7]
2018
NA
7.74%
Medicare database
13.3 Causes and Risk Factors
In a series of 114 TAAs (STAR prostheses) reported in 2013 by Noelle et al., 27 (27/114, 23.6%) ankles had complications following primary surgery, and 21 prostheses (21/114, 18.4%) needed revision surgery (14.9% revision TAA), including 4 (3.5%) patients who required tibiotalar fusion. Patients with BMI > 30 showed a higher rate of complications [5].
In 2015, Horisberger et al. reported that bone augmentation was required for RTAA with large osseous defects. In a 5-year period, 10 patients with aseptic loosening of TAA associated with great bone loss at the tibia, the talus, or both, were treated. Autologous structural iliac crest bone augmentation, as a one- or two-stage approach, was used [9]. Adequate bone stock was successfully reestablished. At an average follow-up of 4 years, 2 of 10 cases had to be converted to tibiotalocalcaneal fusion due to persistent pain with considerable arthrofibrosis (joint stiffness) but not loosening.
Patton et al. analyzed the risk factors for infected TAA in a retrospective comparative study (level III of evidence). A group of 966 patients with TAA were reviewed, and 29 cases of infected TAA (3.2%) were identified. The rate of infection in primary TAA was 2.4%, and in RTAA it was 4%. Risk factors for infection in this study included diabetes, previous ankle surgery, and wound healing problems more than 14 days postoperatively. No significant difference was found between groups with respect to risk factors such as smoking, BMI, and operative time [10]. These authors concluded that given the morbidity of infected TAA, meticulous consideration should be made about performing TAA in patients with multiple previous surgeries and comorbidities that predispose to wound-healing difficulties.
In a prospective comparative study (level II of evidence) reported in 2015, Demetracopoulos et al. found that the outcomes of TAA in younger patients were similar to the outcomes in older patients at early follow-up. Some 395 patients were reviewed with a mean follow-up of 3.5 years (range, 2–5.4 years). Patients were divided into three groups based on age at the time of surgery (<55, 55–70, and > 70 years). The rate of wound complications, need for reoperation, and revision were comparable between groups [11].
Roukis and Elliot could not identify any obvious difference in the reasons for revision between the Salto mobile and the Salto-Talaris (fixed-bearing) prostheses. However, the incidence of revision for the Salto mobile version and Salto-Talaris TAAs was lower than that reported for the Agility and STAR systems without obvious selection (inventor) or publication (conflict of interest) bias [3].